Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier

被引:18
作者
Tashima, Toshihiko [1 ]
机构
[1] Tashima Labs Arts & Sci, 1239-5 Toriyama Cho,Kohoku Ku, Yokohama 2220035, Japan
关键词
drug delivery into the brain; the BBB; receptor-mediated transcytosis; carrier-mediated transport; PROTAC; ubiquitin proteasome system; PROTAC-antibody conjugate; NanoPROTAC; Alzheimer's disease; tau protein degradation; UBIQUITIN-PROTEASOME SYSTEM; ANTIBODY-MEDIATED DELIVERY; DEGRADATION; KNOCKDOWN; PROTEIN; TAU; DISCOVERY; MOLECULES;
D O I
10.3390/antib12030043
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Drug development for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease has challenging difficulties due to the pharmacokinetic impermeability based on the blood-brain barrier (BBB) as well as the blurriness of pharmacodynamic targets based on their unclarified pathogenesis and complicated progression mechanisms. Thus, in order to produce innovative central nervous system (CNS) agents for patients suffering from CNS diseases, effective, selective delivery of CNS agents into the brain across the BBB should be developed. Currently, proteolysis-targeting chimeras (PROTACs) attract rising attention as a new modality to degrade arbitrary intracellular proteins by the ubiquitin-proteasome system. The internalizations of peptide-based PROTACs by cell-penetrating peptides and that of small molecule-based PROTACs through passive diffusion lack cell selectivity. Therefore, these approaches may bring off-target side effects due to wrong distribution. Furthermore, efflux transporters such as multiple drug resistance 1 (MDR1) expressed at the BBB might interrupt the entry of small molecule-based PROTACs into the brain. Nonetheless, intelligent delivery using machinery systems to absorb the nutrition into the brain for homeostasis, such as carrier-mediated transport (CMT) or receptor-mediated transcytosis (RMT), can be established. PROTACs with N-containing groups that are recognized by the proton-coupled organic cation antiporter might cross the BBB through CMT. PROTAC-antibody conjugates (PACs) might cross the BBB through RMT. Subsequently, such small molecule-based PROTACs released in the brain interstitial fluid would be transported into cells such as neurons through passive diffusion and then demonstrate arbitrary protein degradation. In this review, I introduce the potential and advantages of PROTAC delivery into the brain across the BBB through CMT or RMT using PACs in a non-invasive way.
引用
收藏
页数:21
相关论文
共 57 条
[1]   Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer's Disease [J].
Al Mamun, Abdullah ;
Uddin, Md. Sahab ;
Kabir, Md. Tanvir ;
Khanum, Sayema ;
Sarwar, Md. Shahid ;
Mathew, Bijo ;
Rauf, Abdur ;
Ahmed, Muniruddin ;
Ashraf, Ghulam Md .
NEUROTOXICITY RESEARCH, 2020, 38 (01) :8-17
[2]   Pericytes regulate the blood-brain barrier [J].
Armulik, Annika ;
Genove, Guillem ;
Mae, Maarja ;
Nisancioglu, Maya H. ;
Wallgard, Elisabet ;
Niaudet, Colin ;
He, Liqun ;
Norlin, Jenny ;
Lindblom, Per ;
Strittmatter, Karin ;
Johansson, Bengt R. ;
Betsholtz, Christer .
NATURE, 2010, 468 (7323) :557-U231
[3]   PROTAC targeted protein degraders: the past is prologue [J].
Bekes, Miklos ;
Langley, David R. ;
Crews, Craig M. .
NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) :181-200
[4]   Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins [J].
Bonfanti, Silvia ;
Lionetti, Maria Chiara ;
Fumagalli, Maria Rita ;
Chirasani, Venkat R. ;
Tiana, Guido ;
Dokholyan, Nikolay V. ;
Zapperi, Stefano ;
La Porta, Caterina A. M. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[5]   Small-Molecule Modulation of Protein Homeostasis [J].
Burslem, George M. ;
Crews, Craig M. .
CHEMICAL REVIEWS, 2017, 117 (17) :11269-11301
[6]   Unmet health care needs: factors predicting satisfaction with health care services among community-dwelling Canadians living with neurological conditions [J].
Chambers-Richards, Tamara ;
Chireh, Batholomew ;
D'Arcy, Carl .
BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
[7]   Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation [J].
Chu, Ting-Ting ;
Gao, Na ;
Li, Qian-Qian ;
Chen, Pu-Guang ;
Yang, Xi-Fei ;
Chen, Yong-Xiang ;
Zhao, Yu-Fen ;
Li, Yan-Mei .
CELL CHEMICAL BIOLOGY, 2016, 23 (04) :453-461
[8]   Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer [J].
Cimas, Francisco J. ;
Niza, Enrique ;
Juan, Alberto ;
Noblejas-Lopez, Maria del Mar ;
Bravo, Ivan ;
Lara-Sanchez, Agustin ;
Alonso-Moreno, Carlos ;
Ocana, Alberto .
PHARMACEUTICS, 2020, 12 (10) :1-11
[9]  
Crew AP., 2020, Proteolysis targeting chimeric (PROTAC) compound with E3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases, Patent No. [WO2020/041331A1, 2020041331, WO2020041331p.A1]
[10]   Limited Transferrin Receptor Clustering Allows Rapid Diffusion of Canine Parvovirus into Clathrin Endocytic Structures [J].
Cureton, David K. ;
Harbison, Carole E. ;
Cocucci, Emanuele ;
Parrish, Colin R. ;
Kirchhausen, Tom .
JOURNAL OF VIROLOGY, 2012, 86 (09) :5330-5340